Browsing Arthur (Articles) by Author "Takuva, Simbarashe G."

Browsing Arthur (Articles) by Author "Takuva, Simbarashe G."

Sort by: Order: Results:

  • Incidence of cardiometabolic diseases in a Lesotho HIV cohort : evidence for policy decision-making 
    Sebilo, Motlalepula; Ledibane, Neo R.T.; Takuva, Simbarashe G. (AOSIS, 2021-06-28)
    BACKGROUND: Antiretroviral treatment (ART) has been associated with the development of certain cardiometabolic diseases (CMDs). The burden of CMDs amongst ART-experienced patients in sub-Saharan Africa was unknown. OBJECTIVE: ...
  • Safety evaluation of the single-dose Ad26. COV2.S vaccine among healthcare workers in the Sisonke study in South Africa : a phase 3b implementation trial 
    Takuva, Simbarashe G.; Takalani, Azwidhwi; Seocharan, shen; Yende-Zuma, Nonhlanhla; Reddy, Tarylee; Engelbrecht, Imke; Faesen, Mark; Khuto, Kentse; Whyte, Carmen J.; Bailey, Veronique; Trivella, Valentina; Peter, Jonathan; Opie, Jessica; Louw, Vernon; Rowji, Pradeep; Jacobson, Barry; Groenewald, Pamela; Dorrington, Rob E.; Laubscher, Ria; Bradshaw, Debbie; Moultrie, Harry; Fairall, Lara; Sanne, Ian; GailBekker, Linda; Gray, Glenda; Goga, Ameena Ebrahim; Garrett, Nigel (Public Library Science, 2022-06-21)
    Real-world evaluation of the safety profile of vaccines after licensure is crucial to accurately characterise safety beyond clinical trials, support continued use, and thereby improve public confidence. The Sisonke study ...
  • Sisonke phase 3B open-label study : lessons learnt for national and global vaccination scale-up during epidemics 
    Goga, Ameena Ebrahim; Bekker, L-G.; Garrett, Nigel; Takuva, Simbarashe G.; Sanne, I.; Odhiambo, J.; Mayat, F.; Fairall, L.; Brey, Z.; Bamford, L.; Tanna, G.; Gray, G. (Health and Medical Publishing Group, 2022-05)
    Sisonke is a multicentre, open-label, single-arm phase 3B vaccine implementation study of healthcare workers (HCWs) in South Africa, with prospective surveillance for 2 years. The primary endpoint is the rate of severe ...
  • Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition 
    Corey, Lawrence; Gilbert, Peter B.; Juraska, Michal; Montefiori, David C.; Morris, Lynn; Karuna, Shelly T.; Edupuganti, Srilatha; Mgodi, Nyaradzo M.; DeCamp, Allan C.; Rudnicki, Erika; Huang, Yunda; Gonzales, Pedro; Cabello, Robinson; Orrell, Catherine; Lama, Javier R.; Laher, Fatima; Lazarus, Erica M.; Sanchez, Jorge; Frank, Ian; Hinojosa, Juan; Sobieszczyk, Magdalena E.; Marshall, Kyle E.; Mukwekwerere, Pamela G.; Makhema, Joseph; Baden, Lindsey R.; Mullins, James I.; Williamson, Carolyn; Hural, John; McElrath, Juliana; Bentley, Carter; Takuva, Simbarashe G.; Lorenzo, Margarita M. Gomez; Burns, David N.; Espy, Nicole; Randhawa, April K.; Kochar, Nidhi; Piwowar‑Manning, Estelle; Donnell, Deborah J.; Sista, Nirupama; Andrew, Philip; Kublin, James G.; Gray, Glenda; Ledgerwood, Julie E.; Mascola, John R.; Cohen, Myron S. (Massachusetts Medical Society, 2021-03-18)
    BACKGROUND : Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS : We enrolled at-risk cisgender men and transgender persons in ...
  • Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120–MF59 in adults 
    Gray, Glenda E.; Bekker, Linda‑Gail; Laher, Fatima; Malahleha, Mookho; Allen, Mary; Moodie, Zoe; Grunenberg, Nicole; Huang, Yunda; Grove, Doug; Prigmore, Brittany; Kee, Jia J.; Benkeser, David; Hural, John; Innes, Craig; Lazarus, Erica; Meintjes, Graeme; Naicker, Nivashnee; Kalonji, Dishiki; Nchabeleng, Maphoshane; Sebe, Modulakgotla; Singh, Nishanta; Kotze, Philip; Kassim, Sheetal; Dubula, Thozama; Naicker, Vimla; Brumskine, William; Ncayiya, Cleon N.; Ward, Amy M.; Garrett, Nigel; Kistnasami, Girisha; Gaffoor, Zakir; Selepe, Pearl; Makhoba, Philisiwe B.; Mathebula, Matsontso P.; Mda, Pamela; Adonis, Tania; Mapetla, Katlego S.; Modibedi, Bontle; Philip, Tricia; Kobane, Gladys; Bentley, Carter; Ramirez, Shelly; Takuva, Simbarashe G.; Jones, Megan; Sikhosana, Mpho; Atujuna, Millicent; Andrasik, Michele; Hejazi, Nima S.; Puren, Adrian; Wiesner, Lubbe; Phogat, Sanjay; Granados, Carlos Diaz; Koutsoukos, Marguerite; Van Der Meeren, Olivier; Barnett, Susan W.; Kanesa‑Thasan, Niranjan; Kublin, James G.; McElrath, Juliana; Gilbert, Peter B.; Janes, Holly; Corey, Lawrence (Massachusetts Medical Society, 2021-03-25)
    BACKGROUND : A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing ...